Prelude Therapeutics
PublicPrelude Therapeutics is now publicly traded
The data on this page reflects Prelude Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Follow-on Offering
Dec 11, 2023
Total Funding Raised
$147M
Company Overview
Prelude Therapeutics operates in Healthcare and is based in the United States. It has raised $147M.
Prelude Therapeutics is a clinical-stage precision oncology company that discovers and develops small molecule therapies and protein degraders for cancers with high unmet needs. Founded in 2016, the company leverages its expertise in cancer biology and medicinal chemistry to create new chemical entities. Its pipeline includes several drug candidates in clinical development, such as PRT3789 (a SMARCA2 degrader), PRT2527 (a CDK9 inhibitor), and PRT3645 (a CDK4/6 inhibitor). The company is also developing next-generation degrader antibody conjugates (Precision ADCs). Prelude Therapeutics is a public company trading on the Nasdaq stock exchange under the ticker symbol PRLD.
Sector
Healthcare
AI Layer
Non-AI
Prelude Therapeutics Comparables
Compare Prelude Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kirilys Therapeutics | 57% | |
| Alethio Therapeutics | 44% | |
| Altay Therapeutics | 36% |
For institutional investors. Book with your work email.
Prelude Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Dec 11, 2023 | ||||
| VC Round | Aug 24, 2020 | ||||
| VC Round | Jun 12, 2019 | ||||
| Growth Equity | Oct 20, 2017 |
For institutional investors. Book with your work email.
Prelude Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed | VC Round |
Prelude Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.